Peyrin-Biroulet L, Atreya R, Danese S, Lindsay JO, et al. Efficacy and Safety of Risankizumab in Patients with Moderately to Severely Active Crohn's Disease: Interim Results from the SEQUENCE Open-Label Extension Study. J Crohns Colitis 2025 Dec 4:jjaf213. doi: 10.1093.
PMID: 41344313